BioMarin Announces Full Year and Fourth Quarter 2018 Results

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/2/2026

1. CRWD
2. REGN
3. LITE
4. AAPL
5. ABBV
6. MRVL
7. CL
8. LYB
9. TFII
10. SPY

Go back to BioMarin Announces Full Year and Fourth Quarter 2018 Results

BioMarin Pharmaceutical Inc. (BMRN) PT Lowered to $81 at Oppenheimer

February 22, 2019 7:47 AM EST

Oppenheimer analyst Leland Gershell lowered the price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) to $81.00 (from $92.00) while maintaining a Perform rating following the company's 4Q. BMRN reported revenue of $353M, within the mid-range of guidance, but below consensus of $377M, resulting from modest... More

BioMarin Pharma (BMRN) Posts Q4 Loss of $0.03/Share

February 21, 2019 4:25 PM EST

BioMarin Pharma (NASDAQ: BMRN) reported Q4 GAAP EPS of ($0.03), which may not compare to the analyst estimate of ($0.24). Revenue for the quarter came in at $353.2 million versus the consensus estimate of $377.35 million.

GUIDANCE:

BioMarin Pharma sees FY2019 revenue of $1.68-1.75... More